{
    "clinical_study": {
        "@rank": "33444", 
        "arm_group": [
            {
                "arm_group_label": "Adult Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects 18-60 years of age receiving Fluarix/Influsplit SSW 2013-2014"
            }, 
            {
                "arm_group_label": "Elderly Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects aged >60 years of age receiving Fluarix/Influsplit SSW 2013-2014"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess, in adults 18 years of age and above, the\n      immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit SSW\n      2013/2014, containing the three vaccine influenza strains (two A strains and one B strain)\n      for the 2013/2014 season."
        }, 
        "brief_title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix\u00ae/Influsplit SSW\u00ae (2013/2014 Season), in Adults 18 Years of Age and Older", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes can and will comply with the requirements of\n             the protocol.\n\n          -  A male or female aged 18 years or above at the time of vaccination.\n\n          -  Written informed consent obtained from the subject.\n\n          -  Healthy subjects or subjects with well-controlled chronic diseases as established by\n             medical history and clinical examination before entering the study.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n\n               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,\n                  hysterectomy, ovariectomy or post-menopause.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of vaccination.\n\n        Exclusion Criteria:\n\n          -  Participation in previous year's Fluarix registration study (116663).\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccine within 30 days preceding the dose of study vaccine, or planned use\n             during the study period.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs within\n             the six months prior to vaccination. Inhaled and topical steroids are allowed.\n\n          -  Any administration of a long-acting immune-modifying drug within 6 months before\n             study start, or planned administration during the study period.\n\n          -  Administration of immunoglobulins and/or any blood products within the three months\n             preceding the administration of the study vaccine or planned administration during\n             the study period.\n\n          -  Administration of an influenza vaccine within the twelve months preceding the study\n             vaccination.\n\n          -  Receipt of a vaccine other than the study vaccine within 30 days before study\n             vaccination and/or plan to receive any vaccine other than the study vaccine during\n             the entire study period.\n\n          -  Clinically or virologically confirmed influenza infection within the six months\n             preceding the study vaccination.\n\n          -  Acute disease and/or fever at the time of enrollment.\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C/99.5\u00b0F on oral, axillary or tympanic\n                  setting, or \u2265 38.0\u00b0C/100.4\u00b0F on rectal setting. The preferred route for\n                  recording temperature in this study will be axillary.\n\n               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory\n                  infection) without fever may be enrolled at the discretion of the investigator.\n\n          -  Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional\n             abnormality, as determined by physical examination or laboratory screening tests.\n\n          -  Chronic underlying disease (such as cancer, chronic obstructive pulmonary disease\n             under oxygen therapy, insulin-dependent diabetes mellitus), not stabilized or\n             clinically serious.\n\n          -  History of chronic alcohol consumption and/or drug abuse.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination (no laboratory testing required).\n\n          -  History of Guillain-Barr\u00e9 syndrome.\n\n          -  History of allergic disease or reactions likely to be exacerbated by any component of\n             the vaccine including latex.\n\n          -  Anaphylaxis following the administration of vaccine(s).\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions.\n\n          -  Any condition which, in the opinion of the investigator, prevents the subject from\n             participating in the study or would make intramuscular injection unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884519", 
            "org_study_id": "200160", 
            "secondary_id": "2013-000855-42"
        }, 
        "intervention": {
            "arm_group_label": [
                "Elderly Group", 
                "Adult Group"
            ], 
            "description": "Single dose administered intramuscularly in the deltoid region of the non-dominant arm", 
            "intervention_name": "Fluarix/Influsplit SSW\u00ae (2013-2014 season)", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Elderly", 
            "Influenza", 
            "Safety", 
            "Adults", 
            "Immunogenicity"
        ], 
        "lastchanged_date": "November 14, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "01307"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiberg", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "09599"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freital", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "01705"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Schmiedeberg", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "01762"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2013/2014 in People 18 Years of Age and Above", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Humoral immune response in terms of anti-HA antibodies against each of the three vaccine influenza strains", 
                "safety_issue": "No", 
                "time_frame": "At Day 0"
            }, 
            {
                "measure": "Humoral immune response in terms of anti-HA antibodies against each of the three vaccine influenza strains", 
                "safety_issue": "No", 
                "time_frame": "At Day 21"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884519"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage, intensity and duration of solicited local symptoms during a 4-day follow-up period after vaccination. Percentage, intensity, duration and relationship to vaccination of solicited general symptoms during a 4-day follow-up period after vaccination", 
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "During a 4-day follow-up period after vaccination (Days 0-3) (i.e. day of vaccination and 3 subsequent days)"
            }, 
            {
                "description": "Percentage, intensity and relationship to vaccination of unsolicited symptoms during a 21-day follow-up period after vaccination", 
                "measure": "Occurrence of unsolicited symptoms", 
                "safety_issue": "No", 
                "time_frame": "During a 21-day follow-up period after vaccination (Days 0-20) (i.e. day of vaccination and 20 subsequent days)"
            }, 
            {
                "measure": "Occurrence of serious adverse events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period (Day 0-Day 21)"
            }, 
            {
                "measure": "Humoral immune response in terms of anti-HA antibodies against each of the 3 vaccine influenza strains, in subjects aged 18-60 years & >60 years who have & who have not received an influenza vaccine during the 2 influenza seasons prior to season 2012/13", 
                "safety_issue": "No", 
                "time_frame": "At Day 0"
            }, 
            {
                "measure": "Humoral immune response in terms of anti-HA antibodies against each of the 3 vaccine influenza strains,in subjects aged 18-60 years & >60 years who have & who have not received an influenza vaccine during the 2 influenza seasons prior to season 2012/13", 
                "safety_issue": "No", 
                "time_frame": "At Day 21"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}